Personalised medicine start-up DoseMe raises $500K

By Dylan Bushell-Embling
Tuesday, 15 July, 2014

Brisbane-based personalised medicine start-up DoseMe has secured $500,000 in investment funding to help expand its Australian operations and launch overseas.

The company is marketing a proprietary software technology designed to allow clinicians to prescribe medicines based on a patient's individual ability to absorb, process and clear a drug.

It uses simple information including a patient's height, weight and gender to generate complex treatment algorithms based on Bayesian dosing principles. The software then also incorporates patient-specific lab results and continues to learn and adjust doses over time.

DoseMe software is available via mobile devices, a web-based application and as a module to integrate into patient management software. It currently supports 13 medications across four therapeutic areas - anti-microbial, chemotherapy, anti-coagulants and pro-coagulants.

In trials, the software has been shown to be almost twice as effective as traditional dosing methods, the company said in a statement.

DoseMe co-founder and technical director Dr Robert McLeay said funds from this and future capital raisings will be put towards scaling up the company’s operations.

“We now have hospitals, pharmacies and individual doctors using the system in Queensland, Western Australia and Victoria,” he said.

“Future investment rounds will be used to help us scale our business by expanding the product to new medications and also to roll out DoseMe to further international markets.”

Related News

Gene therapy for frontotemporal dementia

A new therapeutic approach for treating frontotemporal dementia — an incurable brain...

Boosting protein in eye cells could prevent vision loss

Increasing the levels of a key protein in the cells at the back of the eye could help protect...

Researchers find the brain network responsible for stuttering

Stuttering appears to be caused by a common brain network, regardless of the aetiology...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd